Health Care & Life Sciences » Biotechnology | Acerus Pharmaceuticals Corp.

Acerus Pharmaceuticals Corp. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
4,763.50
21,640.60
32,442.00
8,364.40
9,561.70
Cost of Goods Sold (COGS) incl. D&A
1,202.00
12,060.70
7,456.20
6,639.20
4,706.60
13,717.10
Gross Income
1,202.00
7,297.10
14,184.40
25,802.90
3,657.80
4,155.50
SG&A Expense
32,263.00
14,058.60
10,268.30
8,638.50
13,263.10
13,556.40
EBIT
33,464.90
21,355.80
3,916.20
17,164.40
9,605.30
17,711.90
Unusual Expense
136.30
2,757.80
16,762.40
49.00
214.20
2,983.70
Non Operating Income/Expense
1,099.80
1,971.50
5,350.40
446.50
1,974.30
1,333.70
Interest Expense
1,146.70
2,972.10
4,851.40
1,562.10
493.20
2,298.10
Pretax Income
33,255.70
25,010.40
12,182.20
15,129.30
11,831.40
24,311.80
Income Tax
329.70
-
628.20
397.50
520.50
37.60
Consolidated Net Income
32,926.00
25,010.40
11,554.00
14,731.80
11,310.90
24,349.40
Net Income
32,926.00
25,010.40
11,554.00
14,731.80
11,310.90
24,349.40
Net Income After Extraordinaries
32,926.00
25,010.40
11,554.00
14,731.80
11,310.90
24,349.40
Net Income Available to Common
32,926.00
25,010.40
11,554.00
14,731.80
11,310.90
24,349.40
EPS (Basic)
0.26
0.14
0.05
0.07
0.05
0.11
Basic Shares Outstanding
130,351.60
176,453.20
200,873.20
209,193.40
213,118.60
224,436.80
EPS (Diluted)
0.25
0.14
0.06
0.07
0.05
0.11
Diluted Shares Outstanding
130,351.60
176,453.20
200,873.20
210,479.30
213,118.60
224,436.80
EBITDA
32,263.00
18,539.40
6,995.60
20,089.80
6,950.80
15,205.10
Non-Operating Interest Income
119.80
103.80
165.00
22.50
27.30
15.60

About Acerus Pharmaceuticals

View Profile
Address
2486 Dunwin Drive
Mississauga Ontario L5L 1J9
Canada
Employees -
Website http://www.aceruspharma.com
Updated 07/08/2019
Acerus Pharmaceuticals Corp. operates as a pharmaceutical company, which engages in the development, manufacture, production, marketing and distribution of women and men's health products. It focuses on the treatment of urology, hormone replacement therapy, and female dysfunction. Its products include Estrace, Natesto, and Tefina.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.